Skip to main content
. 2021 Feb 4;23:1229–1242. doi: 10.1016/j.omtn.2021.01.033

Figure 1.

Figure 1

Association of stromal and immune scores with clinical features and prognosis of lower-grade glioma (LGG)

(A and B) The stromal and immune scores in grade II and III gliomas in TCGA (A) and CGGA (B) datasets. (C and D) The stromal and immune scores in isocitrate dehydrogenase (IDH) mutant and wild-type gliomas in TCGA (C) and CGGA (D) datasets. (E−H) Kaplan–Meier analysis stromal and immune scores in patients with LGG. Data are represented as mean ± SD. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p < 0.0001.